Physician profile
Gregory S Byrd
NPI 1396744488
$843.56
in general payments reported to CMS, 2019-2025
18 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $119 · 2021: $61.50 · 2023: $101 · 2024: $255 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $157.23 | 2021-2025 | |
| Novo Nordisk INC | $147.40 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $66.75 | 2019-2024 | Breztri |
| Merck Sharp & Dohme LLC | $56.85 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $55.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $48.85 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $41.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.50 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $34.71 | 2024-2025 | Shingrix |
| Sanofi-Aventis U.S. LLC | $27.61 | 2019-2020 | |
| Philips North America LLC | $23.97 | 2019 | |
| Dexcom, INC. | $23.32 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $21.74 | 2024 | Rexulti |
| Amgen INC. | $21.69 | 2024 | Otezla, Repatha |
| Abbott Laboratories | $21.07 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20.04 | 2024 | Watchman Access System |
| Dynavax Technologies Corporation | $18.70 | 2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.